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Abstract
Leishmania donovani is an intracellular protozoan parasite that causes visceral leishmaniasis (VL). Antimonials (SSG) have
long been the first-line treatment against VL, but have now been replaced by miltefosine (MIL) in the Indian subcontinent
due to the emergence of SSG-resistance. Our previous study hypothesised that SSG-resistant L. donovani might have
increased in vivo survival skills which could affect the efficacy of other treatments such as MIL. The present study attempts
to validate these hypotheses. Fourteen strains derived from Nepalese clinical isolates with documented SSG-susceptibility
were infected in BALB/c mice to study their survival capacity in drug free conditions (non-treated mice) and in MIL-treated
mice. SSG-resistant parasites caused a significant higher in vivo parasite load compared to SSG-sensitive parasites. However,
this did not seem to affect the strains’ response to MIL-treatment since parasites from both phenotypes responded equally
well to in vivo MIL exposure. We conclude that there is a positive association between SSG-resistance and in vivo survival
skills in our sample of L. donovani strains which could suggest a higher virulence of SSG-R strains compared to SSG-S strains.
These greater in vivo survival skills of SSG-R parasites do not seem to directly affect their susceptibility to MIL. However, it
cannot be excluded that repeated MIL exposure will elicit different adaptations in these SSG-R parasites with superior
survival skills compared to the SSG-S parasites. Our results therefore highlight the need to closely monitor drug efficacy in
the field, especially in the context of the Kala-azar elimination programme ongoing in the Indian subcontinent.
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Introduction
Visceral leishmaniasis (VL) is a major public health challenge in
Sudan, Brazil, Bangladesh, India and Nepal where 90% of all VL
cases occur, but is also prevalent in many other countries in Africa,
South-America, Southern Europe and Asia [1]. In the Indian
subcontinent, VL is caused by Leishmania donovani and is
transmitted by sand flies. Since the disease is lethal if left
untreated, treatment is one of the major pillars in the fight against
VL. Pentavalent antimonials (SSG) are used worldwide as the first-
line treatment against VL since many years, but ever increasing
failure of SSG in some regions has urged the authorities of India,
Nepal and Bangladesh to abandon this treatment and replace it
with the oral drug miltefosine (MIL). The use of MIL in
combination with early diagnosis and vector control are currently
the major pillars of the Kala-azar elimination programme in the
Indian subcontinent [2].
SSG-treatment failure in India and Nepal has been linked to
SSG-resistant parasites [3,4], but the exact mechanism of SSG-
resistance is as yet unclear and presumably multifactorial [5–9].
SSG is known to reinforce the killing mechanisms of macrophages,
the host cells of Leishmania, which contributes to the elimination of
the intracellular parasites [8]. Hence, it is conceivable that SSG-
resistant parasites have acquired superior skills to survive within
the macrophage compared to SSG-sensitive parasites. Based on
the results of our previous study in which SSG-sensitive and SSG-
resistant model strains were characterised on different levels, we
hypothesised that SSG-resistant strains are better equipped to
survive in vivo compared to SSG-sensitive strains [10]. In the
present study, this hypothesis was tested using a large sample of L.
donovani strains which is representative for the parasite populations
circulating in VL-endemic Nepal. In addition, the response to
MIL-treatment of these strains with documented differential SSG-
susceptibility was assessed in the BALB/c mouse model. The latter
allowed evaluating whether the hypothesised superior in vivo
survival skills of SSG-resistant parasites affect the efficacy of
alternative treatments such as MIL.
Materials and Methods
1. Ethical statements
Written informed consent was obtained from the patients and in
the case of children, from the parents or guardians. The study was
approved by the institutional ethical review boards of the Nepal
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Tropical Medicine, Antwerp, Belgium.
Mouse care and experimental procedures were performed
under approval of the Animal Ethic Committee of the Institute of
Tropical Medicine Antwerp (approval ID PAR-018/2) and were
in compliance with the national and international laws for the
protection and welfare of animals.
2. Parasites
The L. (L.) donovani strains described in Table 1 were isolated
from bone marrow aspirates from confirmed VL patients recruited
at the B.P. Koirala Institute of Health Sciences, Dharan, Nepal
[4]. The patients received a full supervised treatment course of
sodium antimony gluconate (SAG) (Albert David Ltd, Calcutta) of
20 mg/kg/day i.m. for 30 days and were followed-up for clinical
and parasitological evaluation at the end of treatment and at 3, 6
and 12 months after start of treatment. The clinical isolates were
identified as L. donovani by PCR-RFLP analysis of cysteine
proteinase b [11]. All isolates were cloned using the micro-drop
method to obtain homogenous working parasite populations [12]
and were subsequently tested for their SSG-susceptibility in an in
vitro amastigote model exposing the parasite to 4 different SSG
concentrations between 3 and 60 mg/ml SSG for 72 hours as
described elsewhere [10]. The ED50 was then calculated using
non-linear regression (sigmoidal dose response curve with variable
slope). Every susceptibility test included the SSG-susceptible
reference strain BPK206/0cl10 in order to determine the activity
index of each strain (i.e. the ratio of the ED50 of the tested strain to
the ED50 of the sensitive reference strain). A strain with an activity
index of 3 or higher is considered to be SSG-resistant as described
elsewhere [4].
3. In vivo infections
In vivo infections were performed as described elsewhere [10].
Briefly, female BALB/c isogenic mice were infected with 10
7
stationary phase promastigotes and randomly allocated into 42
groups of five (3 groups for each of the 14 strains). For the MIL-
treatment study, mice were dosed orally at 10 mg/kg for 5
consecutive days, a dose known to cause 50% reduction in the
hepatic parasite burden [13], starting at day 12 post-infection.
MIL was kindly provided by Aeterna Zentaris GmbH (Germany).
Mice were sacrificed at day 12 (non-treated group only) and day
20 (treated and non-treated group) post-infection to assess the
parasite load in liver and spleen; two time points where the
parasite burden showed to peak during L. donovani infection in
previous experiments [10].
4. Quantification of parasite load and parasite response
to in vivo MIL-treatment
Liver and spleen samples were collected and processed for
quantification of L. donovani as described elsewhere [10]. In
summary, DNA was extracted and assessed by 2 quantitative
PCRs that were run on a LightCycler 480 (Roche): one targeting
kDNA to quantify Leishmania and one targeting the single copy
gene neurotrophin 3 of mice to quantify the amount of murine
cells present in each sample. The parasite burden is described by a
normalised amount of Leishmania per fixed unit of mouse cells,
which allows comparison of parasite load between tissues. The
resulting calibrated normalised relative quantities were calculated
using qbase
plus (Biogazelle) [14] and exported to GraphPad Prism
5 (GraphPad Software) to determine the area under the infection
curve (day 12 to day 20), a measure for the total parasite burden
between day 12 and day 20 in infected BALB/c mice. The efficacy
of MIL-treatment was evaluated by calculating the percentage of
parasite clearance, i.e. the liver parasite load at day 20 of the MIL-
treated group versus the non-treated control group.
Results
1. In vitro SSG-susceptibility
Firstly, the fourteen L. donovani strains derived from Nepalese
clinical isolates were tested for their SSG-susceptibility: 8 strains
were typed as in vitro sensitive to SSG (SSG-S) and 6 strains showed
to be in vitro resistant to SSG (SSG-R) (Table 1).
Table 1. List of strains.
Name International code activity index to SSG SSG-susceptibility
BPK282/0cl4 MHOM/NP/02/BPK282/0cl4 1 S
BPK294/0cl1 MHOM/NP/03/BPK294/0cl1 1 S
BPK043/0cl2 MHOM/NP/02/BPK043/0cl2 0 S
BPK091/0cl9 MHOM/NP/02/BPK091/0cl9 0 S
BPK206/0cl10 MHOM/NP/03/BPK206/0cl10 1 S
BPK080/0cl1 MHOM/NP/02/BPK080/0cl1 1 S
BPK298/0cl8 MHOM/NP/03/BPK298/0cl8 1 S
BPK178/0cl3 MHOM/NP/02/BPK178/0cl3 2 S
BPK190/0cl3 MHOM/NP/03/BPK190/0cl3 .6R
BPK085/0cl3 MHOM/NP/02/BPK085/0cl3 .6R
BPK275/0cl12 MHOM/NP/03/BPK275/0cl12 .6R
BPK164/1cl11 MHOM/NP/02/BPK164/1cl11 .3R
BPK173/0cl3 MHOM/NP/02/BPK173/0cl3 .6R
BPK087/0cl11 MHOM/NP/02/BPK087/0cl11 3 R
All strains are derived from isolates taken before the onset of treatment, except for BPK164/1cl11 which is derived from an isolate taken at the end of treatment. The
activity index to SSG is the ratio of the ED50 of a tested strain to the ED50 of the sensitive reference strain BPK206/0cl10. A strain with an activity index of 3 or higher is
considered to be SSG-resistant as described elsewhere [4].
doi:10.1371/journal.pone.0023120.t001
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In a previous study, SSG-R model strains showed to cause
higher in vivo parasite burdens in BALB/c mice compared to the
SSG-S-strain [10]. In the current validation study, all SSG-S
strains caused a similar parasite burden both in the liver and the
spleen (Fig. 1). In contrast, SSG-R strains displayed a much more
heterogeneous infection profile and an average 8-fold higher
parasite burden in the liver and 3-fold higher parasite burden in
the spleen compared to SSG-S strains (Fig. 1). Important to note is
that the infection level in the spleen followed similar trends as in
the liver, but was in average around 100 fold lower. All data is
available in supporting information file Data S1.
3. In vivo efficacy of MIL-treatment
To assess whether or not the higher infection burden caused by
SSG-R strains also affects their response to in vivo MIL-treatment,
infected mice were treated orally with MIL. In general, SSG-R
and SSG-S strains responded similarly to in vivo MIL-treatment
(mean 6 SEM: 96.1462.30% clearance for the SSG-S group
compared to 87.0266.71% clearance for the SSG-R group in the
liver and 97.7061.75% clearance for SSG-S strains versus
94.0963.62% clearance for SSG-R strains in the spleen), although
some outliers in both groups were observed (Fig. 2). All data is
available in supporting information file Data S1.
Discussion
In the present work, we tested the hypothesis that SSG-R L.
donovani have a better chance for survival in vivo compared to SSG-
S L. donovani [10]. Results obtained with the current sample of 14
clinical L. donovani strains strengthen the hypothesis.
SSG-R strains showed a more variable and markedly higher
capacity to cause in vivo infection compared to SSG-S strains,
hereby suggesting a higher virulence of SSG-R strains. Even
taking the limitations of a VL mouse model into account, these
findings are in agreement with a study that showed an increased
parasite burden in VL patients that eventually showed no response
to SSG-treatment [15]. In another study, we also characterised the
Figure 1. In vivo parasite load in liver and spleen of BALB/c mice caused by SSG-R and SSG-S strains. (A) Heat map showing mean
parasite load in the liver and spleen* of infected mice at day 12 and day 20 post infection. *: spleen values were 100-times multiplied to allow easy
comparison with liver in the heat map. (B) Total in vivo parasite load in infected mice calculated from the area under the day 12 to day 20 infection
curve (AUC). P-values were calculated using the Mann Whitney U test. Horizontal bars indicate the mean and error bars indicate the standard error of
the mean. The SSG-S strains show a homogenous infection profile in both the liver and spleen of infected BALB/c mice. Even though some variation is
observed in the SSG-R group, analyses on both datasets indicate that SSG-R parasites cause a significant higher parasite burden in BALB/c mice
compared to SSG-S parasites.
doi:10.1371/journal.pone.0023120.g001
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transmission and infectivity) of most of the strains which were
analysed here. We could demonstrate that SSG-R strains develop
on average twice as many metacyclic infectious parasites
compared to SSG-S strains [16]. The higher metacyclogenic
capacity of SSG-R strains could explain at least partly the
characteristic higher parasite burden of SSG-R strains observed
here. However, additional traits at the intracellular amastigote
level might very well be co-responsible to maintain this initial
advantage at the start of infection. Host cell manipulation is a well-
known trait of L. donovani and a recent study demonstrated that
SSG-R L. donovani specifically evolved extra mechanisms to
manipulate its host cell to avoid SSG-induced stress [17]. Such
adaptations would not only allow the parasites to survive better
under SSG-pressure, but would also favour their survival in drug
free conditions as observed here in vivo. The higher virulence of
natural SSG-R L. donovani strains could very well contribute their
general fitness. This is in contrast to in vitro induced pentamidine-
or glibenclamide-resistant L. mexicana strains which had respec-
tively a similar or decreased infectivity compared to the wild type
[18,19]. We cannot exclude that L. mexicana behaves differently
compared to L. donovani under SSG-drug pressure. However, we
believe that the differences between our study and to the 2 models
resistant to other drugs discussed above might be due to the ‘host
cell manipulation’ mode of action specific for SSG. In addition, we
report on natural resistance which could differ significantly from in
vitro induced resistance [20].
In a second part of the study, we tested whether the higher in
vivo survival capacity of SSG-R strains could threaten the long
term efficacy of other drugs. In theory, the higher the parasite load
in one particular patient, the harder it is to clear the parasite load
in that patient by drug treatment [15]. We comparatively
evaluated the efficacy of MIL to clear SSG-S and SSG-R strain
infections in BALB/c mice: SSG-R and SSG-S strains seemed to
be equally well cleared by MIL from the spleen and liver of
infected mice. This is in agreement with the in vitro MIL-
susceptible phenotype of the parent isolates of which some of these
strains were derived [21]. These findings are also consistent with
clinical reports of successful MIL-treatment of SSG-failure patients
during a phase-2 trial of MIL in India [22]. Indian studies did
show that some natural SSG-S strains tend to have a higher in vitro
tolerance to MIL compared to SSG-S strains [23] and some
strains were successfully made resistant to MIL by in vitro exposure
in the lab [13,24–26]. However, importantly, natural MIL-R
strains have not been identified in the field yet (unpublished
results).
To conclude, our results suggest that SSG-R L. donovani have a
higher virulence compared to SSG-S L. donovani. Whether or not
this can have an impact on the long term efficacy of MIL in the
Indian subcontinent is not entirely clear from our data on single
exposure to MIL. Therefore, monitoring the efficacy of MIL in
regions were SSG-R strains were reported to be highly prevalent is
of the upmost importance for the current Kala-azar elimination
programme to undertake swift action and switch to new treatment
regimens [27] if necessary.
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